Key Highlights

  • Loss per share was USD 0.04 against an estimate of a USD 0.10 loss.
  • Net loss was USD 3.53 million, compared with USD 8.18 million.
  • Research and development expenses were USD 1.56 million, compared with USD 2.61 million.
  • Cash and cash equivalents were USD 11.71 million at September 30, 2026.

Galectin Therapeutics (NASDAQ:GALT) reported a net loss of USD 3.53 million for the third quarter of 2026, compared with USD 8.18 million in the prior-year quarter. Net loss per common share, basic and diluted, was USD 0.04, compared with USD 0.13, against an estimate of a USD 0.10 loss.

Net loss applicable to common stockholders was USD 3.57 million after preferred stock dividends of USD 37 thousand.

Operating Expenses

Research and development expenses were USD 1.56 million, compared with USD 2.61 million, and general and administrative expenses were USD 1.80 million, compared with USD 1.59 million. Total operating expenses and the operating loss were USD 3.37 million, compared with USD 4.20 million.

Interest income was USD 28 thousand, compared with USD 39 thousand, and interest expense was USD 786 thousand, compared with USD 1.82 million. The change in Fair Value of Derivatives was a gain of USD 594 thousand, compared with a loss of USD 2.21 million. Weighted average shares outstanding were 89,621 thousand, compared with 64,205 thousand.

Nine-Month Results

For the nine months ended September 30, 2026, the net loss was USD 17.69 million, compared with USD 25.34 million, and net loss per common share was USD 0.24, compared with USD 0.40. Research and Development expenses were USD 5.93 million, compared with USD 12.36 million, and general and administrative expenses were USD 5.50 million, compared with USD 4.36 million.

Total operating expenses were USD 11.43 million, compared with USD 16.72 million. Interest expense was USD 4.78 million, compared with USD 5.39 million, and the change in fair value of derivatives was a loss of USD 1.58 million, compared with a loss of USD 3.33 million.

Cash and Going Concern Disclosure

Cash and cash equivalents were USD 11.71 million at September 30, 2026, compared with USD 17.72 million at the prior Balance Sheet date, and total Assets were USD 13.01 million. The filing states that the company believes there is sufficient cash, including availability of its line of credit, to fund currently planned operations through June 2027.

The filing also states that factors described raise substantial doubt about the company's ability to continue as a going concern for a period of 12 months from the issuance date of the financial statements, and that its cash position may not be sufficient to support daily operations after June 2027.

Total current assets were USD 12.91 million, compared with USD 19.44 million, and prepaid expenses and other current assets were USD 1.20 million, compared with USD 1.72 million. The filing states that on December 20, 2021 the second of two promissory notes under the company's Loan agreement was executed, evidencing a second loan in the principal amount of USD 10.0 million.

Galectin Therapeutics Q3 2026 Earnings: Key Takeaways

Galectin Therapeutics reported a third quarter 2026 net loss of USD 3.53 million and a loss per share of USD 0.04. Cash and cash equivalents were USD 11.71 million at September 30, 2026.